Philadelphia Chromosome Negative Clinical Trials

1 recruiting

Philadelphia Chromosome Negative Trials at a Glance

8 actively recruiting trials for philadelphia chromosome negative are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Seattle, Chicago, and New York. Lead sponsors running philadelphia chromosome negative studies include University of Washington, Institute of Hematology & Blood Diseases Hospital, China, and Hospital Universitario Dr. Jose E. Gonzalez.

Browse philadelphia chromosome negative trials by phase

Treatments under study

About Philadelphia Chromosome Negative Clinical Trials

Looking for clinical trials for Philadelphia Chromosome Negative? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Philadelphia Chromosome Negative trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Philadelphia Chromosome Negative clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)84 enrolled274 locationsNCT03739814
Recruiting
Phase 2

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeT Acute Lymphoblastic Leukemia
University of Washington30 enrolled1 locationNCT06738368
Recruiting
Phase 2

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Lymphoblastic LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
City of Hope Medical Center53 enrolled8 locationsNCT06918431
Recruiting
Phase 2

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
University of Washington30 enrolled1 locationNCT05453500
Recruiting
Not Applicable

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

Philadelphia Chromosome Negative ALLAcute Lymphoblastic Leukemia, Adult
Institute of Hematology & Blood Diseases Hospital, China77 enrolled1 locationNCT06481241
Recruiting
Phase 1Phase 2

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Recurrent Burkitt LymphomaRefractory Burkitt LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+6 more
M.D. Anderson Cancer Center276 enrolled1 locationNCT01371630
Recruiting
Phase 2

Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

Philadelphia Chromosome Negative ALLAcute Lymphobkastic LeukemiaAcute Lymphoblastic Leukaemia Recurrent
Hospital Universitario Dr. Jose E. Gonzalez12 enrolled1 locationNCT07039877
Recruiting
Not Applicable

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

Philadelphia Chromosome Negative
University of Chicago20 enrolled1 locationNCT06785324